Issues related to tax reform; international taxation.
2026 · 3rd Quarter (July 1 - Sep 30)
EISAI, INC.
Filed by CROSSROADS STRATEGIES, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 17, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- CROSSROADS STRATEGIES, LLC
- Client
- EISAI, INC.
- Filing UUID
- df22890d-7895-45c9-a590-255f3966f8eb
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to supply chain and tariffs; Section 232 tariff investigation on branded pharmaceuticals.
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; pharmaceutical scheduling; TRICARE coverage issues in FY2027 National Defense Authorization Act (H.R.8800/S.4784); PBM reform; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
General issues related to Medicare and Medicaid, including: Part D Medicare Program; CMMI Drug Pricing Demonstration Programs (GLOBE and GUARD Models); drug pricing; H.R.6130, Alzheimers Screening and Prevention (ASAP) Act of 2025.
Literal federal measure citations: H.R.6130
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.